DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

Information source: Eisai Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Epilepsy

Intervention: Zonegran (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Eisai GmbH

Official(s) and/or principal investigator(s):
Christian Elger, Principal Investigator, Affiliation: Universitatsklinikum Bonn, Klinik fur Epileptologie

Summary

Patients with focal epileptic seizures with or without generalization who are at present treated with one or two antiepileptic drugs are eligible for this study, provided that they fulfill all inclusion criteria and none of the exclusion criteria. Following a baseline phase of 8 weeks duration, the patients are randomised and they receive an initial daily dose of 50 mg zonisamide during the first week. The daily dose is then increased to 200 mg zonisamide in group A or 400 mg zonisamide in group B, respectively. After eight weeks of treatment, the daily dose in group A can be increased to 300 mg in case of insufficient efficacy. Control assessments are performed at the beginning of the study and at the end of the prospective baseline phase, if applicable and after 4, 8, 12, and 16 weeks. At the end of the first, second, and third treatment week, and at the end of week six, the patient is additionally contacted by telephone. Efficacy and safety parameters are assessed at baseline, during all control visits, and at the end of the study.

Clinical Details

Official title: Randomized Trial to Assess Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change in number of epileptic seizures between week 13 and 16 after start of treatment compared to the correspondently normalized base-line phase.

Eligibility

Minimum age: 18 Years. Maximum age: 74 Years. Gender(s): Both.

Criteria:

Inclusion criteria at screening:

- Adult aged between 18 years and 74 years

- Focal epileptic seizures with or without secondary generalization

- Present treatment with one or two antiepileptic drugs (constant dosage during 8 weeks

baseline phase prior to initiation of treatment with zonisamide). Stimulation of the vagus nerve is permitted and will not be counted as antiepileptic drug.

- For women of childbearing potential (postmenopausal for more than 1 year): possible

pregnancy during the study can be excluded (by hysterectomy, sterilization or simultaneous application of two recognized methods of contraception (no oral contraceptives only)

- For male patients with partners of childbearing potential: a safe method of

contraception is practiced during their study participation

- Written consent to participate in the study

Inclusion criteria for randomisation:

- At least 6 focal or clonicotonic seizures documented completely in a seizure diary or

the patient chart during the 8 prospective or retrospective weeks baseline phase. Exclusion criteria at screening:

- Epileptic state during the past year

- Non-epileptic fits

- Generalized epilepsy

- More than 4 weeks of seizure freedom during baseline phase

- Concomitant progressive CNS disease including progressive myoclonus epilepsy

- Concomitant treatment with vigabatrine and / or topiramate

- Hepatic and/or renal insufficiency (creatine > 2mg% or GPT > 2 times ULN)

- Body weight ≤ 40 kg

- (History of) kidney stones; erythrocyturia, family history (in parents, children,

brothers and sisters or grandparents) of kidney stones

- (History of) drug and/or alcohol dependence

- Active psychosis

- Suicide attempt during the past 3 years

- Pre-treatment with zonisamide

- Known hypersensitivity to sulfonamides

- concomitant treatment with neuroleptic drugs

- pregnant or breast feeding woman

- participation in another therapy study within 3 months prior to or during this study

- blood donation planned during or within 4 weeks after the participation in this study

- elective surgery planned during the participation in this study

- patient is not willing or not capable to meet the study demands

- patient does not agree to the forwarding of his/her pseudonymous data

- patient without legal competence

Exclusion criteria for randomisation:

- More than 4 consecutive weeks of freedom from seizure during baseline phase

Locations and Contacts

Epilepsiezentrum Bethel/KSE, Beilefeld 33617, Germany

Charite Campus Virchow-Klinikum, Neurologische Klinik und Poliklinik, Berlin 13353, Germany

Institut fur Diagnostik der Epilepsien Gmbh, Berlin 10362, Germany

Dr. Gunther Schumann, Bochum 44805, Germany

Knappschaftskrankenhaus Bochum-Langendreer, Neurologische Klinik, Bochum 44892, Germany

St. Josephs Hospital, Neurologische Klinik, Bochum 44791, Germany

Dr. Hans Martin Kolbinger, Bonn 53127, Germany

Neuro-Consil Gmbh, Dusseldorf 40212, Germany

Neurologische Klinik der Universitat Erlangen, Erlangen 91054, Germany

Universitatsklinik Essen, Klinik und Poliklinik fur Neurologie, Essen 45147, Germany

Universitatsklinikum Freiburg, Neurozentrum, Freiburg 79106, Germany

Universitatsklinikum Gottingen, Abt. fur klinische Neurophysiologie, Gottingen 37075, Germany

Dr. Heinrich C. Braeuer, Hamburg 22299, Germany

Ev. Krankenhaus Alsterdorf, Epilepsiezentrum Alsterdorf, Hamburg 22337, Germany

Gemeinschaftpraxis fur Neurologie und Psychiatrie, Hamburg 22083, Germany

Epilepsiezentrum Kork, Kehl 77694, Germany

Epilepsiezentrum Kleinwachau, Epilepsieambulanz, Liegau-Augustusbad 01465, Germany

Universitatsklinikum Mannheim, Neurologische Klinik, Ambulanz fur Anfallserkrankte, Mannheim 68167, Germany

Universitatsklinikum, Interdisziplinares Epilepsiezentrum, Marburg 35043, Germany

Klinikum Grosshadern, Neurologische Klinik und Poliklinik, Epilepsie-Ambulanz, Munchen 81377, Germany

Klinikum Offenbach, Neurologie, Offenbach 63069, Germany

Klinik Ernst von Bergmann, Potsdam 14467, Germany

Universitat Regensburg, Klinik un Poliklinik fur Neurologie, Regensburg 93053, Germany

Klinik "Die Weissenau", Anfallsambulanz, Revensburg 88214, Germany

Universitat Rostock, Klinik fur Neurologie und Poliklinik, Rostock 18147, Germany

Universitatsklinik Ulm Poliklinik fur Neurologie, Epilepsieambulanz, Ulm 89075, Germany

Dr. Horst-Schmidt Klinik, Neurologie, Wiesbaden 65199, Germany

Epilepsieklinik Tabor, Bernau, Brandenburg 16321, Germany

Universtitatsklinikum Bonn, Bonn, Nordrhein-Westphalen 53105, Germany

Universtitatsklinikum Munster, Klinik und Poliklinik fur Neurologie, Munster, Nordrhein-Westphalen 48129, Germany

Additional Information

Starting date: May 2005
Last updated: June 26, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017